A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN [IMVAMUNE] smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts greater than 200 - 750/microL.
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 31 Aug 2018 Biomarkers information updated
- 21 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.